What are the specific indications for Pitobrutinib/Pitobrutinib?

Pirtobrutinib is a new highly selective Bruton's tyrosine kinase (BTK) inhibitor. Unlike traditional BTK inhibitors, it is a non-covalent, reversible inhibitor that remains active against C481 site mutations, so it shows important clinical value in patients who are resistant to or relapsed from previous treatments.

The drug's first core indication is the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), provided that the patient has received at least two systemic treatment regimens, which must have included a BTK inhibitor. Mantle cell lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma that is difficult to treat. Patients often relapse after remission after initial treatment. For patients who have used BTK inhibitors, follow-up treatment options are limited. The introduction of pitubrutinib provides a new targeted treatment option for this population.

The second important indication is for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two lines of prior therapy, including BTK inhibitors and BCL-2 inhibitors. CLL/SLL is a slowly progressing B-cell malignancy, but once drug resistance or disease progression occurs, treatment options become narrower. For patients who have experienced treatment failure with both BTK and BCL-2 drugs, Pitobrutinib can still inhibit abnormal signaling pathways at the molecular level and help delay disease progression.

It is worth noting that the design features of pitubrutinib enable it to overcome the resistance mechanism of traditional covalent BTK inhibitors. Even if tumor cells carry mutations such as BTK C481S, it can effectively bind to the target and exert an inhibitory effect. This molecular innovation not only expands the accessibility of treatment, but also extends the benefit period for patients on targeted therapies.

Reference materials:https://go.drugbank.com/drugs/DB17472